Loading…
Underlying
Underlying Price
$6.01
Type
Put
Strike
5
Expiration
Dec 4, 2026
DTE
21d
Moneyness
OTM
Intrinsic
$0.00
IBRX 5 Put Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Nov 13, 2026 | 0d | — | — | 0 | 0 |
| Nov 20, 2026 | 7d | $0.10 | +100.00% | 10 | 354 |
| Nov 27, 2026 | 14d | $0.05 | -58.33% | 15 | 49 |
| Dec 4, 2026 | 21d | — | — | 0 | 0 |
| Dec 11, 2026 | 28d | — | — | 0 | 0 |
| Dec 18, 2026 | 35d | $0.10 | +0.00% | 2 | 9 |
| Dec 24, 2026 | 41d | — | — | 0 | 0 |
| Dec 31, 2026 | 48d | — | — | 0 | 0 |
| Jan 15, 2027 | 63d | $0.28 | +3.70% | 4 | 5,228 |
| Mar 19, 2027 | 126d | $0.45 | +18.42% | 30 | 317 |
| Apr 16, 2027 | 154d | $0.56 | +24.44% | 2 | 5 |
| May 21, 2027 | 189d | $0.53 | -3.64% | 2 | 15 |
| Aug 20, 2027 | 280d | $1.71 | +0.00% | 5 | 5 |
| Nov 19, 2027 | 371d | $1.50 | +3.45% | 5 | 46 |
| Jan 21, 2028 | 434d | $0.90 | -8.16% | 2 | 983 |
| Mar 17, 2028 | 490d | $1.50 | -7.98% | 20 | 26 |
| Jan 19, 2029 | 798d | $2.42 | +0.00% | 4 | 6 |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.